Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 10/20 | 0.87 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897012 | 1.00 | MAP3K5 (0.87) | MAP3K5HIF1ANAPEX1MAPTMEN1 | |
| SCHEMBL6786647 | 0.92 | MAP3K5 (0.74) | MAP3K5HIF1ANMAPTMEN1PKM | |
| SCHEMBL3897422 | 0.91 | MAP3K5 (0.78) | MAP3K5APEX1MAPTMEN1KMT2A | |
| SCHEMBL3897417 | 0.91 | MAP3K5 (0.78) | MAP3K5APEX1MAPTMEN1KMT2A | |
| SCHEMBL25152806 | 0.89 | MAP3K5 (0.75) | MAP3K5HIF1ANAPEX1MAPTMEN1 | |
| SCHEMBL3905770 | 0.87 | HIF1AN (0.83) | MAP3K5HIF1ANMAPTMEN1PKM | |
| SCHEMBL3905768 | 0.87 | HIF1AN (0.83) | MAP3K5HIF1ANMAPTMEN1PKM | |
| SCHEMBL3893490 | 0.86 | MAP3K5 (1.00) | MAP3K5HIF1ANAPEX1MAPTMEN1 | |
| SCHEMBL6720214 | 0.86 | MAP3K5 (1.00) | MAP3K5HIF1ANAPEX1MAPTMEN1 | |
| SCHEMBL3893493 | 0.86 | MAP3K5 (1.00) | MAP3K5HIF1ANAPEX1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20070202118-A1 | NOVEL PEROXIREDOXIN DEFENSE SYSTEM FROM MYCOBACTERIUM TUBERCULOSIS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2004043955-A1 | RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202118-A1 | NOVEL PEROXIREDOXIN DEFENSE SYSTEM FROM MYCOBACTERIUM TUBERCULOSIS | PRDX3, PRDX5, DLD | MAP3K5 3431/4885HIF1AN 1474/4885APEX1 424/4885 |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | MAP3K5 1092/4885HIF1AN 647/4885APEX1 1572/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | MAP3K5 1460/4885HIF1AN 714/4885APEX1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.